It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What ar ...

McKesson Corporation (MCK) reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $6.18, which missed the Zacks Consensus Estimate of $6.34 by 2.52%. The bottom line also declined 14% on a year-over-year basis.GAAP EPS was $6.02, up 5.4% from the year-ago quarter’s level.Revenue DetailsRevenues of $76.36 billion missed the Zacks Consensus Estimate by 3%. However, the top line increased 11% year over year, primarily driven by growth in the U.S. Pharmaceutical segment.Full-Years ResultsMcKes ...

For the quarter ended March 2024, McKesson (MCK) reported revenue of $76.36 billion, up 10.8% over the same period last year. EPS came in at $6.18, compared to $7.19 in the year-ago quarter.The reported revenue represents a surprise of -3.00% over the Zacks Consensus Estimate of $78.72 billion. With the consensus EPS estimate being $6.34, the EPS surprise was -2.52%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

McKesson (MCK) came out with quarterly earnings of $6.18 per share, missing the Zacks Consensus Estimate of $6.34 per share. This compares to earnings of $7.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.52%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $7.05 per share when it actually produced earnings of $7.74, delivering a surprise of 9.79%.Over the last four quarters, ...

Financial Performance - In fiscal 2024, sales to the ten largest customers accounted for approximately 69% of total consolidated revenues, with CVS Health Corporation alone contributing about 28%[65]. - Research and development expenses for fiscal years 2024, 2023, and 2022 were $77 million, $89 million, and $70 million, respectively[67]. - The largest supplier accounted for 12% of total purchases in fiscal 2024, while the ten largest suppliers represented approximately 67% of total purchases[66]. - Approximately 43% of total trade accounts receivable at March 31, 2024, were from the ten largest customers, with CVS accounting for about 24%[65]. Operational Efficiency - The U.S. Pharmaceutical segment operates 27 distribution centers in the U.S., enhancing safety, reliability, and product availability through technology investments[18]. - Investments in new distribution centers aim to increase scale and capacity, improve efficiency through automation, and enhance regulatory compliance capabilities[34]. - McKesson's U.S. Pharmaceutical segment provides solutions to retail national accounts, community pharmacies, institutional healthcare providers, and oncology partners[19]. - The company has implemented Six Sigma methodology to improve processes, reduce costs, and enhance service accuracy and safety[18]. Customer and Market Engagement - The company has connections with over 50,000 pharmacies and approximately 950,000 providers, supporting over 650 biopharma brands[28]. - McKesson's retail businesses face strong competition from various global, national, regional, and local retailers, including chain and independent pharmacies[36]. - McKesson operates a national network of approximately 4,500 independently-owned pharmacies under the Health Mart brand, enhancing operational excellence and patient care[21]. Employee Development and Well-being - The company is committed to investing in employee development, offering training, coaching, and financial assistance for higher education opportunities[48]. - McKesson's leadership emphasizes a strong culture with I CARE values (Integrity, Inclusion, Customer-First, Accountability, Respect, Excellence) and ILEAD leadership behaviors[47]. - The company is committed to investing in employee well-being, offering health and wellness benefits, savings programs, and flexible work arrangements[48]. - McKesson's compensation program is designed to attract and retain talent, with a focus on internal equity, market competitiveness, and pay for performance[48]. - The company actively seeks employee feedback through annual surveys to assess engagement and satisfaction levels[49]. Regulatory Compliance - McKesson maintains extensive controlled substance monitoring and reporting programs to comply with regulations from the DEA, FDA, and other agencies[53]. - The implementation of the Inflation Reduction Act of 2022 is expected to change how Medicare pays for drugs, aimed at reducing drug prices[56]. - The FDA established a one-year stabilization period for certain Drug Supply Chain Security Act requirements, allowing trading partners to implement systems until November 27, 2024[60]. - The company is subject to various regulatory requirements, including those from the FDA and DEA, which increase compliance costs and operational complexity[51]. - Environmental regulations may impose costs related to compliance and cleanup obligations at closed sites[62]. - Compliance with various cybersecurity and data protection laws adds to operational complexity and costs[61]. Technology and Innovation - The company is exploring potential AI capabilities and related data analytics to improve productivity and efficiency across its enterprise[34]. - McKesson's oncology technology and insights business, Ontada, supports clinical, financial, and operational needs of oncology practice customers[27]. - McKesson's Prescription Technology Solutions segment offers comprehensive solution suites that span the entire patient journey, improving health outcomes[28]. - McKesson's RxO Advisory Services provide data-driven supply chain management and pharmacy optimization solutions[23]. Strategic Decisions - The company announced its intention to exit European businesses, divesting the majority during fiscal 2022 and 2023, with remaining operations in Norway[33]. - The company has transitioned the distribution of COVID-19 vaccines commercially through its customer pharmaceutical distribution channels[26]. - McKesson Canada operates approximately 2,700 banner pharmacies and 400 owned pharmacies, providing integrated pharmacy care and industry-leading service levels[32]. - McKesson Canada provides comprehensive specialty health services and biopharma services, including a national network of specialty pharmacies and Canada's largest accredited private infusion clinics[31]. Investor Relations - The company routinely posts material information for investors on its website and social media channels, including updates on business developments and financial performance[72]. - Forward-looking statements in the annual report may involve risks and uncertainties that could cause actual results to differ materially from projections[69]. - Investors are encouraged to monitor the company's website for automated email alerts regarding important updates[72].

McKesson Corporation Fiscal 2024 Financial Results Fiscal 2025 Outlook May 7, 2024 Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the ...

McKESSON CORPORATION REPORTS FISCAL 2024 FOURTH QUARTER AND FULL YEAR RESULTS Fourth Quarter Highlights: • Consolidated revenues of $76.4 billion increased by 11%. • Earnings per diluted share from continuing operations of $6.02 increased $0.31. • Adjusted Earnings per Diluted Share of $6.18 decreased by 14%. Full Year Highlights: • Consolidated revenues of $309.0 billion increased by 12%. • Earnings per diluted share from continuing operations of $22.39 decreased $2.66. • Adjusted Earnings per Diluted Shar ...

Wall Street analysts expect McKesson (MCK) to post quarterly earnings of $6.34 per share in its upcoming report, which indicates a year-over-year decline of 11.8%. Revenues are expected to be $78.72 billion, up 14.2% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnin ...

The market expects McKesson (MCK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 7, 2024, might help the stock move higher if these key numbers are better th ...

McKesson (MCK) closed the latest trading day at $543.30, indicating a +0.62% change from the previous session's end. This change lagged the S&P 500's 1.02% gain on the day. Meanwhile, the Dow experienced a rise of 0.4%, and the technology-dominated Nasdaq saw an increase of 2.03%.The prescription drug distributor's stock has climbed by 0.58% in the past month, exceeding the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15%.Investors will be eagerly watching for the performance of McKesson in its ...